<DOC>
	<DOCNO>NCT02548780</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetic profile , safety , efficacy LifePearl™ microspheres load Doxorubicin treatment unresectable HCC .</brief_summary>
	<brief_title>LifePearl-Doxo Pharmacokinetic ( PK ) Study</brief_title>
	<detailed_description>This multicentre , prospective dose escalation/PK study , design assess clinical performance LifePearl™ bead load Doxorubicin primary treatment unresectable HCC chemoembolization . Data study use supportive data post CE-mark approval . The main objective study evaluate safety pharmacokinetic profile LifePearl™ bead load Doxorubicin treatment patient unresectable liver cancer ( HCC ) chemoembolization . This measure treatment-related complication plasma level Doxorubicin peripheral blood . In addition , objective tumour response assess computed tomography MRI . Two cohort patient evaluate : Cohort I assess safety ( dose escalation ) pharmacokinetic profile ; Cohort II ass pharmacokinetic profile , safety efficacy doxorubicin dose determine Cohort I .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patient least 18 year old HCC diagnose accord updated American Association Study Liver Diseases ( AASLD ) EASLEuropean Organization Research Treatment Cancer ( EORTC ) criteria BCLC B patient BCLC A patient candidate curative treatment ( resection , transplantation , ablation ) failed/recurred resection/ablation Tumor burden ( locate one two lobe ) sufficiently selectively embolized require dose LifePearl load doxorubicin Performance status ( PS ) 0 Normal liver compensate cirrhosis preserve liver function ( ChildPugh A , score ≤ 6 point ) without ascites absence diuretic treatment Total bilirubin ≤2.0 mg/dl Adequate renal function ( serum creatinine &lt; 1.5 X ULN ) Patient provide write informed consent Patient affiliate social security equivalent system ( France ) Patient previously treat intraarterial therapy HCC sorafenib Eligible curative treatment ( resection/radiofrequency ablation ( RFA ) , transplantation therapy ) ; Advanced liver disease : ChildPugh 's BC class active gastrointestinal bleeding , encephalopathy . Bilirubin level &gt; 2.0 mg/dl ; Advanced tumoral disease : BCLC class C ( vascular invasion even segmental , extrahepatic spread cancerrelated symptoms=PS 12 ) D class ( WHO performance status 3 4 ) Patient another primary tumor Patient refractory ascites diuretic treatment Patient history biliary tree disease biliary dilatation Portal vein thrombosis , portosystemic shunt , hepatofugal blood flow absent portal blood flow liver area treat Contraindication multiphasic CT MRI ( e.g . allergy contrast medium ) ; Any contraindication embolization local doxorubicine treatment ; Patient currently participate investigational drug device study complete primary endpoint clinically interfere current study endpoint In Investigator 's opinion patient ( ) comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study Pregnant breastfeed woman Patient judicial protection ( France )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>unresectable</keyword>
</DOC>